Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
fmx114 save search
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-08-10 (Crawled : 13:00) - globenewswire.com
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: -20.95%
H: 6.25%
C: -2.5%
fmx114 treatment dermatitis trial therapeutics phase 2b
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic DermatitisTop-line Efficacy Results Expected in Approximately 6 to 8 Weeks
Published: 2022-06-17 (Crawled : 14:00) - biospace.com/
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: 8.54%
H: 0.0%
C: -5.74%
fmx114 treatment expected trial therapeutics phase 2b
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-06-17 (Crawled : 12:20) - globenewswire.com
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: 8.54%
H: 0.0%
C: -5.74%
fmx114 treatment dermatitis trial therapeutics phase 2b
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-04-07 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
fmx114 treatment dermatitis trial therapeutics positive phase 2b
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-01-19 (Crawled : 14:00) - biospace.com/
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: 2.19%
H: 2.99%
C: -5.58%
fmx114 treatment atopic dermatitis dermatitis phase 1b trial therapeutics phase 1 phase 2b
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: -0.88%
H: 4.42%
C: -1.77%
treatment atopic dermatitis dermatitis trial enroll
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
Published: 2021-03-01 (Crawled : 13:03) - globenewswire.com
VYNE | $2.37 2.16% 360K
|
Health Technology
|
| O: 4.02%
H: 2.71%
C: -4.12%
dermatitis atopic dermatitis program
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3831 151.54% 190M
|
Consumer Services
CZOO | $11.04 121.24% 11M
|
LICN | $0.9107 62.63% 14M
|
BOF | $1.87 59.83% 100M
|
AMST | $3.18 59.0% 67M
|
Technology Services
MTC | $3.31 47.77% 7.7M
|
Technology Services
MULN | News | $3.915 43.41% 12M
|
Information
WIMI | $1.04 43.37% 17M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
RILY | $30.01 38.17% 11M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.